Biosimilars and Follow-On Biologics: World Market 2011-2021


April 1, 2011
152 Pages - SKU: VSG6451879
License type:
Table of Contents Related Reports
Biosimilars and Follow-On Biologics: World Market 2011-2021

  enlarge


How will the biosimilars and follow-on biologics market develop this decade? Our new report shows you that emerging industry and market's revenue potential from 2011 to 2021.

This report covers drugs in the biosimilar medicinal product and follow-on protein product field. You will assess events, opportunities and activities shaping that industry. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our new study shows you revenue prospects for biosimilars and follow-on biologics at total world, submarket and national levels to 2021. What products will expand that market from 2011 to 2021? What effects will regulations have? Our work provides answers you need.

We forecast revenues for monoclonal antibodies and anti-inflammatory fusion proteins (AIFPs), insulin, erythropoietins, interferons, granulocyte-colony stimulating factor (G-CSF) and growth hormones. You will see how those drugs are changing the biologics market.

We help you to assess the biosimilar/follow-on biologic industry's strengths, weaknesses, trends and revenue opportunities to 2021. You will see where those products are heading.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Industry and market analysis to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, analysis of companies, products and regulations, and opinions from our survey.

We include 106 tables and charts and three research interviews (shown in the accompanying lists). Our study helps you to understand this industry and its potential.

Biosimilars and Follow-On Biologics: World Market 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
  • You will receive hard data for the biosimilars and follow-on biologics industry and market - especially our revenue forecasting to 2021
  • You will discover revenue forecasts for biosimilar/follow-on biologic product classes to 2021 and a revenue prediction for the overall market
  • You will see revenue forecasts for the overall biologics market, in total and by class, to 2021
  • You will find revenue forecasts for leading national markets to 2021 (US, Japan, Germany, France, Spain, UK, Italy, China and India)
  • You will assess the prospects for companies in biosimilars/follow-on biologics, with discussions of leading players and product development in the industry
  • You will read discussions of biosimilar drug approvals and regulatory policies
  • You will investigate competition and opportunities in the market
  • You will see what will stimulate and restrain the industry and market
  • You will analyse opportunities for established companies and those seeking to enter the biosimilars/follow-on biologics market
  • You will view opinion from our survey, including full interview transcripts.
That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for biologic drugs.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


Additional Information


Report Excerpt

7.3.7 Italy

Branded products dominate the Italian pharmaceutical market. The use of branded biologics is common and, as a result, the biosimilars market is only small, with total sales of $0.01bn in 2010. There is little incentive for doctors to prescribe generics, or for wholesalers to distribute them. However, recent reforms in pharmaceutical pricing are likely to increase the use of generics and, consequently, biosimilars in the market, visiongain predicts. In 2010, as part of healthcare budgetary cuts, the Italian government announced that it would only reimburse the cheapest version of a prescription drug. Additionally, reimbursement of oncology biologics in hospitals will now be based on the individual patient’s response, with treatment being withdrawn from non-responding patients.

Companies Listed

3SBio
Abbott
Accelsior
Actavis
AgResearch
Amgen
Amphastar Pharmaceuticals
Apotex
AstraZeneca
Avesta Biotherapeutics and Research
Avesthagen
AxiCorp
Baxter
Bayer
Beijing Shuanglu Medicine Co
Bio Mabs
Bio Sidus
Bioceuticals Arzneimittel
Biocon
Biogen Idec
BioGenerix
Biopartners (a Bioton subsidiary)
Biotechnology Regulatory Authority of India (BRAI) [India]
Bioton
Biovel Life Sciences (no part of Ranbaxy)
BresaGen (now part of Hospira)
Bristol-Myers Squibb (BMS)
Cangene
CCL Pharmaceuticals
Cell Pharm
Celltrion
Celltrion Healthcare (a subsidiary of Celltrion)
Center for Biologics Evaluation and Research (CBER - FDA) [US]
Center for Drug Evaluation and Research (CDER - FDA) [US]
Chiron (part of Novartis)
CinnaGen
Cipla
CJ Corporation
Committee for Medicinal Products for Human Use (CHMP)
CT Arzneimittel
Daiichi Sankyo
Department of Biotechnology (India)
Dong-A Pharmaceutical
Dow Pharma
Dr. Reddy's Laboratories
Egis Nyrt
Elan
Eli Lilly
European Generic Medicines Association (EGA)
European Medicines Agency (EMA)
Feron
Food and Drug Administration (FDA) [US]
Genentech (now part of Roche)
GeneScience
Genetic Engineering Approval Council (GEAC) [India]
Geoden Richter
Getz Pharma
GlaxoSmithKline (GSK)
GlycoFi (now part of Merck & Co)
GTC Biotherapeutics
Hefei Life Science Park Investment & Development Co
Hemopharm
Hexal (part of Novartis)
Hikma
Hospira
Hualida Biotech
Human Genome Sciences
Insmed
Institutional Biosafety Committees (IBSC) [India]
Intas Biopharmaceuticals
Isu Abxis Co
JCR Pharmaceuticals
Johnson & Johnson (J&J)
Kissei Pharmaceutical Co
Kyowa Hakko Kirin Co
LFB Biotechnologies
LG
LG Chem
LG Life Sciences
Lonza
MabPharm
Marvel LifeSciences
Medice Arzeimittel Pütter
Meditab Specialities
Merchant & Gould P.C.
Merck & Co.
Merck BioVentures
Merck KGaA
Ministry of Health Labour and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical Co
Momenta Pharmaceuticals
Mylan
National Institute for Biological Standards and Control (NIBSC) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
Neose Technologies
Nobel Ilac
Novartis
Novo Nordisk
Parexel
Parexel Consulting
Pfenex
Pfizer
Pharmasset
PrimaPharm
Provincial Institute for the Control of Pharmaceutical and Biologic Products [China]
Qilu Pharmaceutical Co
Quintiles
Ranbaxy Laboratories
ratiopharm
Recombinant DNA Advisory Committee (RDAC) [India]
Reliance GeneMedix
Reliance Group
Reliance Life Sciences
Review Committee on Genetic Manipulation (RCGM) [India]
Roche
Samsung
Sandoz (a division of Novartis)
sanofi-aventis
Schering-Plough (now part of Merck & Co.)
SciGen (a Bioton subsidiary)
Sheffield Bio-Science
Stada Arzneimittel
State Biosafety Coordination Committees (SBCC) [India]
State Food and Drug Administration [China]
Teva Pharmaceutical Industries
The Australian Therapeutic Goods Administration (TGA) [Australia]
Tonghua Dongbao Pharmaceutical Co
Upsher-Smith Laboratories
Wockhardt
World Health Organisation (WHO)
Zenotech Laboratories (part of Ranbaxy)
Zydus Cadila

More Biosimilars reports by Visiongain

Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 by Visiongain
What are the commercial prospects for pharmaceutical freeze drying? Visiongain's report gives you revenue predictions to 2022 for equipment, services and applications. You ...
Single-Use Bioreactors for Pharma: World Market 2012-2022 by Visiongain
Disposable bioreactors market is expanding - discover areas of highest potential growth What does the future hold for single-use bioreactor technologies? Visiongain's report ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Biosimilars Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!